Rating Change
JP Morgan analysts reiterated a Overweight rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on August 03, 2026.
reiterateNASDAQ:IONS
JP Morgan Reiterates Overweight Rating on Ionis Pharmaceuticals, Inc. (IONS)
Rating Change JP Morgan analysts reiterated a Overweight rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on August 03, 2026. Market Context Ionis Pharmaceuticals, Inc.
Market Context
Ionis Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $54.49 with a market capitalization of $12.6B. The stock has gained 33.9% over the past 52 weeks.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ionis Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ionis Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 03, 2026 | JP Morgan | Overweight | N/A |
| Jul 30, 2026 | Wells Fargo | Overweight | N/A |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 21, 2026 | Guggenheim | Buy | N/A |
| Jul 16, 2026 | Wolfe Research | Peer Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View IONS Stock Page
Frequently Asked Questions
What does a Overweight rating mean for IONS?
A Overweight rating from JP Morgan reflects the analyst's outlook on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IONS forecast page.